<DOC>
	<DOCNO>NCT00805662</DOCNO>
	<brief_summary>Placebo-controlled study . Application nasal oxytocin ( 8 IU ) intrauterine insemination 86 patient .</brief_summary>
	<brief_title>Nasal Oxcytocin During IUI</brief_title>
	<detailed_description>Between 2004 2007 , 86 patient primary secondary infertility enrol prospective , randomize , double-blinded study tertiary-care infertility center . A total 132 homologous intrauterine insemination ( IUI ) cycle ( mean : 1.5 cycle ) perform . All patient give inform consent . The study approve Human Ethics Committee Medical Faculty Ludwig-Maximilians-University ( LMU ) Munich German Federal Institute Drugs Medical Products ( BfArM ) ( Bundesinstitut für Arzneimittel und Medizinprodukte ) consent study . Inclusion criterion couple idiopathic infertility , polycystic ovary syndrome ( PCOS ) / male subfertility ( table 1 ) . Maximum female age 42 year . Infertility workup include standard gynecological examination transvaginal sonography use 7.5 MHz probe . Patients display sign symptoms anomaly uterine fusion defect , submucosal fibroid , active endometriosis acute inflammation exclude study . Further prerequisites endocrine serum parameter ( FSH , LH , estradiol , testosterone , SHBG , DHEA-S , Prolaktin , TSH ) cycle day 2-5 within normogonadotropic range evidence hyperandrogenemia , thyroid dysfunction hyperprolactinemia . 15 patient diagnose polycystic ovary syndrome ( PCOS ) accord Rotterdam ESHRE/ASRM Consensus Workshop Group ( 26 ) . In patient fallopian tube document patent sonographic contrast hysterosalpingography ( Echovist® 200 , Bayer Vital GmbH , Leverkusen , Germany ) chromo-laparoscopy . Infections Hepatitis B C HIV exclude couple negative serological test . In patient protective titer rubella virus confirm . IUI perform natural ( n=31 , 23 % ) stimulate cycle ( n=101 , 77 % ) . Stimulation do daily s.c. 37 IU 50 IU recombinant FSH ( Puregon , Organon GmbH , Oberschleißheim , Germany ) start day 3 day 5 menstrual cycle . Cycles monitor repeated transvaginal sonography determination serum estradiol LH . Ovulation induction ( OI ) do 5.000 IU hCG ( Predalon , Organon GmbH , Oberschleißheim , Germany ) s.c. 250 μg recombinant hCG ( Ovitrelle , Serono GmbH , Unterschleißheim , Germany ) s.c. soon one maximum three follicle reach mean diameter 20 mm LH exceed 10 mIU/mL combination follicle mean diameter least 16 mm . IUI do 24h-36h OI . Data uterine , ovarian endocrine parameter time ovulation induction ( OI ) summarize table 2 . Homologous semen sample gain masturbation abstinence time 3-5 day . After liquification 30 min analysis semen parameter carry accord World Health Organization guideline ( 27 ) . Details result summarize table 2 . Sperm morphology analyse accord WHO guideline least one semen analysis precede study 3 month . The sperm preparation conduct utilizing density gradient separation describe WHO manual ( 27 ) . Sil Select ( FertiPro N.V. , Beernem , Belgium ) use instead Percoll recommend WHO manual ( 27 ) . The density gradient ( 90 % /45 % ) achieve separation sperm centrifugation 500 g 20 minute . The pellet wash 5.0 mL Universal IVF Medium ( Medi Cult , Jyllinge , Denmark ) , centrifuge 5 minute 500 g resuspend total volume 0.3 mL . After processing , semen evaluate sperm concentration motility . Only couple total progressive motile sperm count ( TPMC ) least 1 million processed sperm suspension include study . Data summarize table 2 . Oxytocin placebo , fill identical nasal spray applicator label `` A '' `` B '' , deliver pharmacy department LMU-Klinikum , Campus Grosshadern . Probes blind clinical staff patient . The verum consist Synthocinon®-Spray ( Novartis Pharma GmbH , Nürnberg , Germany ) . According manufacturer one nasal spray pump consist 4 IU oxytocin . In addition verum contain chlorobutanol , methyl-4-hydroxybenzoat propyl-4-hydroxybenzoat preservation . Placebo consist isotonic NaCl solution 0.01 % benzalkoniumchloride und 0.1 % Na-EDTA preservation . The nasal spray keep 4°C replace monthly . Patients randomly assign either group A group B ( double-blinded ) use computer generate randomization list . Codes A B broken last study patient complete pregnancy test . Data patient variable group summarize table 2 . All patient ask squeeze spray air control pump mechanism apply two snuff ( =8 IU oxytocin ) nasal spray label A B respectively one nostril directly IUI . Ten minute completion IUI patient ask fill form document possible side effect . Each follow complaint ask quantified scale level 1 ( =no side effect ) level 10 ( =maximum side effect ) : low abdominal pain , nasal mucosal irritation , nausea , headache vomiting . The primary endpoint study evidence chorionic sac transvaginal sonography 21-23 day IUI positive serum hCG test . Statistical analysis carry use SPSS 16.0 . Binary logistic regression apply calculation Odds ratio likelihood ratio test . For comparison , p &lt; 0.05 consider significant .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Inclusion criterion couple idiopathic infertility , polycystic ovary syndrome ( PCOS ) / male subfertility . Age 1842 In patient fallopian tube document patent sonographic contrast hysterosalpingography ( Echovist® 200 , Bayer Vital GmbH , Leverkusen , Germany ) chromolaparoscopy . Infections Hepatitis B C HIV exclude couple negative serological test . In patient protective titer rubella virus confirm . Patients display sign symptoms anomaly uterine fusion defect , submucosal fibroid , active endometriosis acute inflammation exclude study . Further prerequisites endocrine serum parameter ( FSH , LH , estradiol , testosterone , SHBG , DHEAS , Prolaktin , TSH ) cycle day 25 within normogonadotropic range evidence hyperandrogenemia , thyroid dysfunction hyperprolactinemia . 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>IUI</keyword>
	<keyword>oxytocin</keyword>
</DOC>